Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer
1 clinical trials · Condition
◉ Watch Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer
| Record | Firm | Date |
|---|---|---|
| A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers (NCT01460134) | Celldex Therapeutics | 2011-10-01 |
Track Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer automatically
Every clearance here is in the API, with alerts when new ones post.